Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

N
Nösslinger, Thomas

3rd Medical Department for Haematology and Oncology, Hanusch Hospital
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Thomas Nösslinger
Favorite
Nadeu, Ferran

Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Ferran Nadeu
Favorite
Naeem, Aishath

Dana-Farber Cancer Institute
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Aishath Naeem
Favorite
Naidu, Kartik
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Kartik Naidu
Favorite
Nair, Binoj

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Binoj Nair
Favorite
Nakamura, Naoya

Tokai University
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Naoya Nakamura
Favorite
Narkhede, Mayur

University of Alabama at Birmingham
1148 - Time to treatment initiation in 17p-deleted Chronic Lymphocytic Leukemia has no influence on overall survival
Mayur Narkhede
Favorite
Nath, Rajneesh

Banner MD Anderson Cancer Center
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Rajneesh Nath
Favorite
Navarrete, Marcelo

Universidad de Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Marcelo Navarrete
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Marcelo Navarrete
Favorite
Navarro, Hugo
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Hugo Navarro
Favorite
Navarro, Víctor

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Víctor Navarro
Favorite
Navrkalova, Veronika

Department of Internal Medicine – Hematology and Oncology, Masaryk University and University Hospital Brno
4004 - Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients
Veronika Navrkalova
Favorite
Naya, Hugo

Bioinformatics Unit at Institut Pasteur de Montevideo
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Hugo Naya
Favorite
Near, Aimee

IQVIA
2007 - Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Aimee Near
Favorite
Newrzela, Sebastian
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Sebastian Newrzela
Favorite
Ng, Anita

The Feinstein Institutes for Medical Research, Northwell Health
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Anita Ng
Favorite
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Anita Ng
Favorite
Ng, David

ARUP Laboratories
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
David Ng
Favorite
Nguyen, Bastien

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Bastien Nguyen
Favorite
Nguyen-Khac, Florence

Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Florence Nguyen-Khac
Favorite
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Florence Nguyen-Khac
Favorite
Nguyen, Phuong-Hien

Department I for Internal Medicine; Center for Molecular Medicine Cologne CMMC, University of Cologne
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Phuong-Hien Nguyen
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Phuong-Hien Nguyen
Favorite
Niemann, Carsten

Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University
1053 - Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
Carsten Niemann
Favorite
1101 - Association between hypertension and overall survival in chronic lymphocytic leukemia
Carsten Niemann
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Carsten Niemann
Favorite
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Carsten Niemann
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Carsten Niemann
Favorite
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Carsten Niemann
Favorite
Niesman, Michael

MingSight Pharmaceuticals, Inc.
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Michael Niesman
Favorite
Nilsen, Lene Skou

University Hospital of North Norway
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Lene Skou Nilsen
Favorite
Nilsson, Ingmar

Department of Medicine, Karlstad Hospital
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Ingmar Nilsson
Favorite
Nivet, Thomas
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Thomas Nivet
Favorite
Nodzon, Lisa

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Lisa Nodzon
Favorite
Noel, Robin

Institut Paoli Calmettes
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Robin Noel
Favorite
Nomdedéu, Josep

Hospital de la Santa Creu i Sant Pau
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Josep Nomdedéu
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Josep Nomdedéu
Favorite
Norén, Torbjörn

10 Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Torbjörn Norén
Favorite
Noto, Alessandro

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Alessandro Noto
Favorite
Noviski, Mark

Nurix Therapeutics, Inc.
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Mark Noviski
Favorite
Noy, Ariela

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Ariela Noy
Favorite
Nudel, Morgane
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Morgane Nudel
Favorite
Nunes, Jessica

The Ohio State University
1046 - Unveiling the Role of Siglec-6 in Regulating B Cell Functions: Implications for Chronic Lymphocytic Leukemia Therapeutics
Jessica Nunes
Favorite